https://doi.org/10.4081/hmr.v2i7.433

Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 150
PDF: 259
Untitled (): 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

E Gallo
support@pagepress.org
Even though the target of chemotherapy and radiotherapy is the tumor cell, normal rapidly dividing tissues are affected and injuries of the upper and lower gastrointestinal tract are frequent. Oral mucositis (OM) is the most common complication following myeloablative therapy and Hematopoietic Stem Cell Transplantation (HSCT). Almost all patients receiving chemotherapy and radiotherapy treatment experience some degree of OM. In particular, about 40% of patients receiving standard chemotherapy, 75-90 % of bone marrow transplant patients treated with high-dose conditioning regimen and nearly all patients treated with radiotherapy for head and neck cancers develop OM.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Gallo, E. (2009). Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.433
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).